Trametinib and Hydroxychloroquine (HCQ) Combination Treatment in KRAS-Mutated Advanced Pancreatic Adenocarcinoma: Detailed Description of Two Cases.

Camila Bragança XavierKatia R MarchettiTiago B CastriaDenis L F JardimGustavo S Fernandes

Published in: Journal of gastrointestinal cancer (2020)

Our real-life data regarding KRAS-mutated PDAC patients who received treatment with the MEK inhibitor trametinib combined with hydroxychloroquine after experiencing disease progression are consistent with the preclinical data, pointing to the clinical benefits of this regimen.

Keyphrases

wild type
electronic health record
stem cells
mesenchymal stem cells
cell proliferation
deep learning
cell therapy
data analysis
pi k akt
artificial intelligence